Are sigma receptor modulators a weapon against multiple sclerosis disease?

Future Med Chem

Experimental Neurology Unit, Department of Medicine & Surgery & Milan Center for Neuroscience, University of Milan Bicocca, Via Cadore 48, Monza 20900, Italy.

Published: November 2017

Effective therapies for multiple sclerosis (MS) are still missing. This neurological disease affects more than 2.5 million people worldwide. To date, biological immunomodulatory drugs are effective and safe during short-term treatment, but they are suitable only for parenteral administration and they are expensive. Accordingly, academic and industrial environments are still focusing their efforts toward the development of new MS drugs. Considering that neurodegeneration is a contributory factor in the onset of MS, herein we will focus on the crucial role played by sigma 1 receptors (S1Rs) in MS. A pilot study was performed, evaluating the effect of the S1R agonist (R)-RC33 on rat dorsal root ganglia experimental model. The encouraging results support the potential of S1R agonists for MS treatment.

Download full-text PDF

Source
http://dx.doi.org/10.4155/fmc-2017-0122DOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
8
sigma receptor
4
receptor modulators
4
modulators weapon
4
weapon multiple
4
sclerosis disease?
4
disease? effective
4
effective therapies
4
therapies multiple
4
sclerosis missing
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!